Anthony Ditonno News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Search jobs 07-Apr-2021 Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to Not Stand for Re-Election at the Upcoming 2021 Annual Meeting of Stockholders MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that Ronald R. Blanck, D.O., Gregory Pepin and Chris A. Rallis ...

Published: Mar 02, 2021   New Board appointments strengthen Tenax with world-class expertise in cardiovascular drug development, commercial strategy, and business development New Directors will provide significant guidance as Tenax is poised to advance its two leading drug candidates into late-stage clinical testing Transformational step as Tenax strengthens its positioning as a leading specialty pharmaceutical company focused on cardio-pulmonary therapeutics   a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases ...

MORRISVILLE –Tenax Therameputics is acquiring an Illinois-based biotech firm with a promising hypertension treatment and named that company’s cofounder as its chief medical officer. Tenax (Nasdaq: TENX) shares soared 38% to $2.45 shortly after the announced deal for PH Precision Med (PHPM) and the appointment of Stuart Rich, MD, as its CMO early Tuesday. Tenax is paying some 12 million shares of stock to PHPM shareholders. PHPM is focused on a potential treatment of pulmonary arterial hypertension, and its lead candidate has received Orphan Drug Designation from the FDA. The drug – a ...